Vaxfab Enterprises Ltd (542803)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Vaxfab Enterprises' revenue was ₹0.4 Cr, and net profit ₹-3.1 Cr; the operating margin was -1412.1%.
| Q1 FY27 (₹ Cr) | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹0.4 | — | -97.4% |
| Operating profit | ₹-5.6 | — | to loss |
| Net profit | ₹-3.1 | — | loss narrowed |
| EPS (₹) | -1.20 | — | loss narrowed |
| Operating margin | -1412.1% | — | — |
📢 Recent Corporate Announcements
Vaxfab Enterprises has approved raising funds up to Rs 45.00 crore through a rights issue of equity shares of face value Rs 10 each. The proposed fundraise represents approximately 94% of the company's net worth (Rs 48 crore) and 4.5% of its market capitalization (Rs 995 crore). The board also approved the Draft Letter of Offer to be filed with BSE Limited and constituted a Rights Issue Committee. Issue price, rights entitlement ratio, and record date will be determined subsequently.
- Rights issue approved for an aggregate amount of up to Rs 45,00,00,000 (Rs 45 crore)
- Proposed securities are equity shares with a face value of Rs 10.00 each
- Draft Letter of Offer approved for filing with BSE Limited
- Rights Issue Committee formed comprising 3 members under Chairman Ravindra Ashokbhai Joshi
Vaxfab Enterprises has approved raising funds up to Rs 45.00 crore through a rights issue of equity shares of face value Rs 10 each. The proposed fundraise represents approximately 94% of the company's net worth (Rs 48 crore) and 4.5% of its market capitalization (Rs 995 crore). The board also approved the Draft Letter of Offer to be filed with BSE Limited and constituted a Rights Issue Committee. Issue price, rights entitlement ratio, and record date will be determined subsequently.
- Rights issue approved for an aggregate amount of up to Rs 45,00,00,000 (Rs 45 crore)
- Proposed securities are equity shares with a face value of Rs 10.00 each
- Draft Letter of Offer approved for filing with BSE Limited
- Rights Issue Committee formed comprising 3 members under Chairman Ravindra Ashokbhai Joshi
Vaxfab Enterprises Ltd has scheduled a Board of Directors meeting on October 01, 2026, to consider augmenting financial resources via fundraising. The proposed methods include preferential allotment, rights issue, QIP, ADR/GDR, FCCBs, or other securities in one or more tranches. The quantum and structure of the capital raise remain unspecified. The company's trading window is closed from September 25, 2026, until 48 hours post-board meeting.
- Board meeting scheduled for Thursday, October 01, 2026
- Fundraise proposed via equity, convertible instruments, rights issue, QIP, or FCCBs
- Trading window closed effective September 25, 2026 until 48 hours after the meeting
Vaxfab Enterprises has approved the allotment of 8,26,761 equity shares of face value Rs 10 each upon conversion of warrants on a preferential basis to 9 investors. The shares were allotted at an issue price of Rs 21.02 each, bringing in the remaining conversion consideration of Rs 15.765 per warrant (aggregating to ~Rs 1.30 crore). Following this allotment, the company's paid-up equity capital increased to Rs 25.83 crore across 2,58,26,406 equity shares. The newly allotted shares rank pari-passu with existing equity shares.
- Allotted 8,26,761 equity shares of Rs 10 face value upon warrant conversion to 9 investors
- Conversion price received was Rs 15.765 per warrant against total issue price of Rs 21.02 per share
- Paid-up equity share capital expanded to Rs 25,82,64,060 comprising 2,58,26,406 equity shares
- Results in ~3.2% dilution of the post-allotment equity base
Vaxfab Enterprises Limited has approved the allotment of 8,26,761 equity shares of face value Rs 10 each at an issue price of Rs 21.02 per share upon the conversion of preferential warrants. The company received the balance exercise amount of Rs 15.765 per warrant from 9 investors, generating approximately Rs 1.30 crore in cash. Following this allotment, the paid-up share capital increases to Rs 25.83 crore divided into 2,58,26,406 equity shares.
- Allotment of 8,26,761 equity shares of face value Rs 10 at Rs 21.02 per share upon warrant conversion
- Received balance exercise price of Rs 15.765 per warrant across 9 investors (~Rs 1.30 crore)
- Post-allotment paid-up share capital increased to Rs 25,82,64,060 comprising 2,58,26,406 equity shares
- Dilution from this allotment represents approximately 3.20% of the expanded share capital
Vaxfab Enterprises reported a sharp decline in financial performance for the quarter ended June 30, 2026. Standalone revenue from operations slumped to ₹0.40 Cr (₹40.00 Lakhs) compared to ₹14.57 Cr in Q1 FY26. Standalone net loss stood at ₹5.84 Cr versus a net profit of ₹0.39 Cr in the year-ago period, heavily impacted by notional losses on fair valuation of investments. On a consolidated basis, revenue stood at ₹0.40 Cr with a net loss attributable to owners of ₹3.04 Cr.
- Standalone revenue from operations fell sharply to ₹0.40 Cr (₹40.00 Lakhs) from ₹14.57 Cr in Q1 FY26
- Standalone net loss widened to ₹5.84 Cr (₹584.09 Lakhs) compared to a net profit of ₹0.39 Cr in Q1 FY26
- Consolidated net loss attributable to owners stood at ₹3.04 Cr (₹303.65 Lakhs)
- Management attributed the loss primarily to a notional loss on fair valuation of investments under Ind AS 109
- Paid-up equity share capital increased to ₹25.26 Cr (₹2525.96 Lakhs) from ₹8.40 Cr
Vaxfab Enterprises reported a standalone net loss of ₹5.84 crore for Q1 ended June 30, 2026, compared to a net profit of ₹0.39 crore in the same period last year and ₹5.02 crore in the preceding quarter. Standalone revenue from operations dropped 97.3% YoY to ₹0.40 crore from ₹14.57 crore in Q1 FY26. Management noted the loss was primarily driven by notional mark-to-market losses on fair valuation of investments under Ind AS 109, which pushed standalone other expenses to ₹5.84 crore. On a consolidated basis, net loss attributable to owners came in at ₹3.04 crore, while paid-up equity share capital increased to ₹25.26 crore from ₹8.40 crore.
- Standalone revenue from operations fell 97.3% YoY to ₹0.40 crore (40.00 lakhs) from ₹14.57 crore in Q1 FY26
- Standalone net loss stood at ₹5.84 crore (584.09 lakhs) vs a net profit of ₹0.39 crore in Q1 FY26
- Loss primarily driven by notional fair valuation loss on investments, pushing other expenses to ₹5.84 crore
- Paid-up equity share capital expanded sharply to ₹25.26 crore (2525.96 lakhs) from ₹8.40 crore
Vaxfab Enterprises has incorporated a wholly-owned subsidiary (WOS) in the UAE named Al Rafa Enterprise FZ-LLC on August 6, 2026. The subsidiary is based in the Ras Al Khaimah Economic Zone and will engage in diverse activities including seeds trading, packaging materials, and IT consultancy. The initial capital is being paid in cash at AED 1,000 per share, though the total investment amount was not disclosed. This move marks an international expansion for the company, which reported a FY26 revenue of Rs 94.11 Cr and a net profit of Rs 3.64 Cr.
- 100% ownership established in the new UAE-based entity Al Rafa Enterprise FZ-LLC
- Incorporation completed on August 6, 2026, under the Ras Al Khaimah Economic Zone Authority
- Initial share price for the subsidiary set at AED 1,000.00 per share
- Business mandate covers 5+ sectors including Seeds Trading, IT Consulting, and General Trading
- Company reported TTM revenue of Rs 94 Cr and Net Worth of Rs 48 Cr prior to this expansion
Vaxfab Enterprises Ltd has scheduled a board meeting for August 14, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company reported a TTM revenue of Rs 94 Cr, but quarterly performance has shown significant volatility, with revenue dropping from Rs 55.04 Cr in September 2025 to Rs 8.83 Cr in March 2026. The trading window for designated persons has been closed since July 01, 2026, in anticipation of these results.
- Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results
- Trading window closed from July 01, 2026, until 48 hours after result submission
- TTM revenue stands at Rs 94 Cr with a thin TTM PAT of Rs 1 Cr
- Previous quarter (Mar 2026) revenue was Rs 8.83 Cr, a sharp decline from Rs 55.04 Cr in Sep 2025
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
